Patent · US Active

Benzimidazol-2-amines as MIDH1 inhibitors

US10138226B2 · kind B2 · utility

6Cited by

2References

29Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Hartmut Rehwinkel · Berlin, DE
Marcus Bauser · Berlin, DE
Katja Zimmermann · Mülheim an der Ruhr, DE
Stefan Kaulfuß · Berlin, DE
Roland Neuhaus · Berlin, DE

Key dates

Filing date	Oct 20, 2015
Grant date	Nov 27, 2018
Priority date	—
Expiry date	Oct 20, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D235/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.